Novo Nordisk
NVO
1,511 hedge funds and large institutions have $33.4B invested in Novo Nordisk in 2023 Q4 according to their latest regulatory filings, with 289 funds opening new positions, 582 increasing their positions, 443 reducing their positions, and 59 closing their positions.
390% more first-time investments, than exits
New positions opened: 289 | Existing positions closed: 59
31% more repeat investments, than reductions
Existing positions increased: 582 | Existing positions reduced: 443
21% more capital invested
Capital invested by funds: $27.6B → $33.4B (+$5.86B)
21% more call options, than puts
Call options by funds: $719M | Put options by funds: $596M
16% more funds holding
Funds holding: 1,307 → 1,511 (+204)
13% more funds holding in top 10
Funds holding in top 10: 62 → 70 (+8)
0.57% more ownership
Funds ownership: 8.74% → 9.31% (+0.57%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.19B |
| 2 |
SGA
Sustainable Growth Advisers
Stamford,
Connecticut
|
+$374M |
| 3 |
JP Morgan Chase
New York
|
+$265M |
| 4 |
Amundi
Paris,
France
|
+$134M |
| 5 |
Capital International Investors
Los Angeles,
California
|
+$128M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$235M |
| 2 |
WCM Investment Management
Laguna Beach,
California
|
-$228M |
| 3 |
Jennison Associates
New York
|
-$88.2M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$79.2M |
| 5 |
BlackRock
New York
|
-$74.6M |
NVO Hedge Fund Activity: Q4 2023 in Review
1,511 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q4 2023, worth a combined $33.4B — up 21% from $27.6B a quarter earlier.
Buyers outnumbered sellers: 289 funds opened new NVO positions and 59 closed out — a net gain of 230 holders — while 582 added to existing stakes and 443 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.19B. The largest seller was Renaissance Technologies, cutting an estimated $235M.
- 1,511 institutional investors held Novo Nordisk (NVO) as of Q4 2023, up from 1,307 in Q3 2023.
- Funds reported $33.4B of Novo Nordisk stock for Q4 2023, up 21% quarter-over-quarter.
- 289 funds opened new Novo Nordisk positions in Q4 2023 and 59 closed out, a net change of +230 holders.
- The largest Novo Nordisk buyer in Q4 2023 was Morgan Stanley, an estimated $1.19B added.
- The largest Novo Nordisk seller in Q4 2023 was Renaissance Technologies, an estimated $235M sold.
Based on aggregated 13F filings for Q4 2023.